Skip to main content
Clinical Trials/IRCT201206131030N10
IRCT201206131030N10
Completed
Phase 2

Comparison of Therapeutic and Adverse Effects of Leupromer (Iranian Formulated LHRH agonist) and Eligard in patients with Metastatic Prostate Cancer

Iran Polymer and petrochemical institute0 sites98 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Metastatic prostate cancer.
Sponsor
Iran Polymer and petrochemical institute
Enrollment
98
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
Iran Polymer and petrochemical institute

Eligibility Criteria

Inclusion Criteria

  • 1\-Paetient with metastatic prostate cancer who examined by paraclinical diagnostics. (i.e.: needle biopsy of prostate, pathologic trans rectal sonography bone scan, CT\-scan and MRI) and assessd their bone and viscera; 2\- Must be Iranian; 3\-Signed the testimonial form by own awareness. 4\-Confidency of patient cooperation with administering drug; 5\-Assitance of patient to come with scheduled program. Exclusion criteria: 1\-Disorder in hypothalamus\-hypophysis\-gonadal axis; 2\-Previous treatment with GnRH analog or other hormonal treatment or chemotherapy in last three month; 3\-Radioteraohy in last two month; 4\-Malignant with active origin; 5\-Need to adjuvant treatment; 6\-Urinary obstruction or spinal cord compression; 7\- Administering with other drug (cooperating with another study); 8\- Dissatisfaction of patient; 9\-Probability of impossibility of following by patient; 10\-drug addiction; 11\- allergy to GnRH analogs or any kind of GnRH.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials